- Home
- EWTX vs CGAU Comparison
EWTX vs CGAU Comparison
Compare EWTX & CGAU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EWTX | CGAU |
|---|---|---|
| Founded | 2017 | 2002 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Precious Metals |
| Sector | Health Care | Basic Materials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7B | 3.9B |
| IPO Year | 2021 | 2021 |
Fundamental Metrics
Financial Performance| Metric | EWTX | CGAU |
|---|---|---|
| Price | $45.40 | $16.22 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 3 |
| Target Price | ★ $39.00 | $16.67 |
| AVG Volume (30 Days) | ★ 1.6M | 1.5M |
| Earning Date | 05-07-2026 | 04-29-2026 |
| Dividend Yield | N/A | ★ 1.16% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $25.17 |
| Revenue Next Year | N/A | $13.62 |
| P/E Ratio | ★ N/A | $11.74 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.31 | $6.71 |
| 52 Week High | $48.40 | $21.17 |
Technical Indicators
Market Signals| Indicator | EWTX | CGAU |
|---|---|---|
| Relative Strength Index (RSI) | 64.21 | 49.91 |
| Support Level | $29.03 | $15.12 |
| Resistance Level | N/A | $19.95 |
| Average True Range (ATR) | 2.71 | 0.62 |
| MACD | 0.66 | 0.06 |
| Stochastic Oscillator | 74.16 | 60.71 |
Price Performance
Historical ComparisonAbout EWTX Edgewise Therapeutics Inc.
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The company's product candidates are Sevasemten, EDG-7500, EDG-003, and EDG-15400. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies, including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company's products are currently in different stages of their development, being developed to target key muscle proteins and modulators to address a broad array of muscle diseases.
About CGAU Centerra Gold Inc.
Centerra Gold Inc is principally focused on operating, developing, exploring and acquiring gold and copper properties in North America, Turkey, and other markets world-wide. The company reportable operating segments are Oksut; Mount Milligan; and Molybdenum. It derives maximum revenue from Mount Milligan segment. Geographically, it operates in Turkey, United States, and Canada.